The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces differentiation of human breast cancer cells.

被引：0
|
作者：
Munster, PN
Rosen, N
Rifkind, R
Marks, P
Richon, V
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CLINICAL CANCER RESEARCH | 2001年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
356
引用
收藏
页码：3725S / 3725S
页数：1
相关论文
共 50 条
  • [21] Suppressive Effect of the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) on Hepatitis C Virus Replication
    Sato, Ayami
    Saito, Yoshimasa
    Sugiyama, Kazuo
    Sakasegawa, Noriko
    Muramatsu, Toshihide
    Fukuda, Shinya
    Yoneya, Mikiko
    Kimura, Masaki
    Ebinuma, Hirotoshi
    Hibi, Toshifumi
    Ikeda, Masanori
    Kato, Nobuyuki
    Saito, Hidetsugu
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2013, 114 (09) : 1987 - 1996
  • [22] In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
    Tambunan, Usman S. F.
    Bramantya, N.
    Parikesit, Arli A.
    BMC BIOINFORMATICS, 2011, 12
  • [23] Histone deacetylase inhibitors: Development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers
    Richon, VM
    Zhou, XB
    Rifkind, RA
    Marks, PA
    BLOOD CELLS MOLECULES AND DISEASES, 2001, 27 (01) : 260 - 264
  • [24] A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    Kelly, W
    O'Connor, O
    Richon, VM
    Tong, W
    Rao, TD
    Chiao, J
    O'Brien, JP
    Rifkid, RA
    Marks, PA
    Scher, HI
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S88 - S88
  • [25] Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, in relapsed leukemias
    不详
    CLINICAL LYMPHOMA, 2004, 5 (02): : 78 - 79
  • [26] The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL
    Butler, Lisa M.
    Liapis, Vasilios
    Bouralexis, Stelios
    Welldon, Katie
    Hay, Shelley
    Thai, Le M.
    Labrinidis, Agatha
    Tilley, Wayne D.
    Findlay, David M.
    Evdokiou, Andreas
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (04) : 944 - 954
  • [27] Growth inhibition of renal cancer cells by histone deacetylase inhibitors, suberoylanilide hydroxamic acid (SAHA) and PXD101
    Min, Gyeong Eun
    Hwang, Jung Jin
    Yoo, Changhee
    Kim, Mi-Joung
    Kim, Yong-Sook
    Song, Kanghyon
    Kim, Seong Cheol
    Kwon, Taek Min
    Park, Jong Yeon
    Ahn, Tai Young
    Kim, Choung-Soo
    JOURNAL OF UROLOGY, 2008, 179 (04): : 40 - 40
  • [28] Anti-angiogenic effect of vorinostat (suberoylanilide hydroxamic acid, SAHA), a histone deacetylase inhibitor, in CTCL lesions
    Ni, X.
    Kelly, C.
    Talpur, R.
    Zhang, C.
    Breuer-McHam, J.
    Richon, Vm
    Duvic, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : 2 - 2
  • [29] The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Confers Acute Neuroprotection After Intracerebral Hemorrhage in Mice
    Sangeetha Sukumari-Ramesh
    Cargill H. Alleyne
    Krishnan M. Dhandapani
    Translational Stroke Research, 2016, 7 : 141 - 148
  • [30] The hybrid polar cytodifferentiation agent suberoylanilide hydroxamic acid (SAHA) is a potent inhibitor of histone deacetylase activity.
    Richon, VM
    Breslow, R
    Rifkind, RA
    Marks, PA
    BLOOD, 1998, 92 (10) : 598A - 598A
12345